Pegylated Long-Acting Human Growth Hormone Is Well-Tolerated in Healthy Subjects and Possesses a Potential Once-Weekly Pharmacokinetic and Pharmacodynamic Treatment Profile

Abstract

After a single sc administration of NNC126-0083 in healthy male volunteers, a sustained dose-dependent pharmacodynamic response was induced. These results indicate that NNC126-0083 has the potential for an efficacious, well-tolerated, once-weekly rhGH compound in the treatment of GH deficiency in adults.